U.S. Markets open in 9 hrs 5 mins

Global Dengue Fever Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight

·9 min read
DelveInsight Business Research LLP
DelveInsight Business Research LLP

Dengue Fever Pipeline constitutes 20+ key companies continuously working towards developing 20+ Dengue Fever treatment therapies, analyzes DelveInsight

Las Vegas, USA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Dengue Fever Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight

Dengue Fever Pipeline constitutes 20+ key companies continuously working towards developing 20+ Dengue Fever treatment therapies, analyzes DelveInsight

DelveInsight’s Dengue Fever Pipeline Insight 2022’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Dengue Fever pipeline domain.

Some of the essential takeaways from the Dengue Fever Pipeline report:

  • DelveInsight’s Dengue Fever Pipeline analysis depicts a robust space with 20+ active players proactively working to develop 20+ pipeline treatment therapies.

  • Some of the key Dengue companies working to develop potential drug candidates to improve the Dengue Fever treatment scenario include Kino Pharma, Emergex Vaccines, Abivax, Plex Pharmaceuticals, Takeda, Merck Sharp & Dohme, Immunoforge, Chugai Pharmaceutical Co., Ltd, Codagenix, Biotron Ltd, GlaxoSmithKline, Ennaid therapeutics, AbViro LLC, Medigen Vaccine Biologics Corp., Atea Pharmaceuticals, Visterra, Janssen Research & Development, Globavir Biosciences, Serum Institute of India, BioNet Asia, and many others.

  • Essential Dengue Fever pipeline therapies such as Research programs: anti-RNA virus therapeutics, viral budding inhibitors, ABX220, Infectious diseases therapeutics program, CDX DENV, AT-752, VIS513, JNJ-64281802, TV003, V 503, TAK-003, AV-1, PepGNP-Dengue, GBV 006, Dengushield, Pentavalent dengue-zika vaccine, and others are under development in different phases of clinical studies.

  • In June 2021, Emergex Vaccines Holding Limited announced that it has achieved regulatory approval for a Phase I clinical trial of its Dengue vaccine. The study has received approval from Swiss regulatory agencies and the first participants are expected to be enrolled soon.

  • In May 2021, Takeda Pharmaceutical Company Limited announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual’s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 clinical trial namely - Tetravalent Immunization against Dengue Efficacy Study (TIDES). TIDES enrolled more than 20,000 healthy children and adolescents ages four to 16 years in dengue-endemic countries in Latin America and Asia.

  • In August 2021, Atea Pharmaceuticals, Inc. announced the publication of data demonstrating the in vitro and in vivo activity of AT-752 against dengue virus infection, in the journal, Antimicrobial Agents and Chemotherapy. The article titled, “Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses,” can be accessed here. The published data demonstrate that AT-752 has potent in vitro activity against multiple dengue virus serotypes and other flaviviruses tested, reduces viremia, and improves survival in an animal model of dengue disease.

  • In October 2021, Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration with the KU Leuven Rega Institute and the KU Leuven Centre for Drug Design and Discovery (CD3), the publication of new preclinical data in the journal Nature showing that an early-stage compound with a novel mechanism of action could potentially treat all serotypes of dengue fever and provide a period of protection against acquiring the dengue virus. Janssen is now moving its dengue program into clinical development.

Request a sample and discover more about the scope of the report offerings @ Dengue Fever Emerging Therapies

The Dengue Fever pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Dengue Fever products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Dengue Fever pipeline landscape.

Dengue Fever Overview

Dengue Fever is a disease caused by four dengue viruses spread by the Aedes aegypti mosquito. The Center for Disease Control and Prevention (CDC) estimates that at least 400 million cases of dengue fever occur across the globe every year. It is also known as breakbone fever due to the severity of muscle spasms and joint pain, dandy fever, or seven-day fever because of the usual duration of symptoms of Dengue. It begins abruptly after a typical incubation period of 5-7 days, and the course follows 3 phases: febrile, critical, and convalescent. Common Dengue fever symptoms generally last for 2 to 7 days and can include sudden high fever, severe headache, swollen lymph glands, severe joint and muscle pains, skin rash. Common laboratory findings for Dengue Fever diagnosis include thrombocytopenia, leukopenia, elevated aspartate aminotransferase. The virus antigen is detectable by ELISA, polymerase chain reaction, or virus isolation from body fluids.

Find out more about the disease and recently developing strategies @ Dengue Fever Pipeline Assessment

Dengue Fever Pipeline Drugs

Drug

Company

Phase

MoA

RoA

Research programs: anti-RNA virus therapeutics

Kino Pharma

Discovery

Virus replication inhibitors

NA

Research programs: viral budding inhibitors

Biotron Ltd

Discovery

Viral protein inhibitors

NA

ABX220

Abivax

Discovery

NA

NA

Infectious diseases therapeutics program

Plex Pharmaceuticals

Preclinical

Peptide hydrolase inhibitors

NA

CDX DENV

Codagenix

Preclinical

Immunostimulants

Parenteral

AT-752

Atea Pharmaceuticals

Phase I

DNA-directed RNA polymerase inhibitors

Oral

PepGNP-Dengue

Emergex Vaccines

Phase I

Virus replication inhibitors

Intradermal

VIS513

Visterra

Phase I

Immunomodulators

Parenteral

JNJ-64281802

Janssen Research & Development

Phase II

NA

Oral

TV003

Merck & Co

Phase III

Immunostimulants

Subcutaneous

V 503

Takeda

Phase III

Immunostimulants

Intramuscular

TAK-003

Takeda

Preregistration

Immunostimulants

Subcutaneous

AV-1

AbViro

Phase I

Immunostimulants

Intravenous

Dengushield

Serum Institute of India

Phase I

NA

Intravenous

Learn more about the novel and emerging Dengue Fever pipeline therapies @ Dengue Fever Pipeline Analysis

Dengue Fever Therapeutics Assessment

The Dengue Fever Pipeline report proffers an integral view of the Dengue Fever emerging novel therapies segmented by Stage, Product Type, Mechanism of Action, Route of Administration, and Molecule Type.

Scope of the Dengue Fever Pipeline Report

  • Coverage: Global

  • Therapeutic Assessment By Dengue Fever Product Type: Mono, Combination, Mono/Combination

  • Therapeutic Assessment By Dengue Fever Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates

  • Therapeutics Assessment By Dengue Fever Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous

  • Therapeutics Assessment By Dengue Fever Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules

  • Therapeutics Assessment By Dengue Fever Therapies Mechanism of Action: Immunostimulants, DNA-directed RNA, polymerase inhibitors, Viral protein inhibitors, Immunomodulators, Viral nonstructural protein inhibitors

  • Key Dengue Fever Companies: Kino Pharma, Emergex Vaccines, Abivax, Plex Pharmaceuticals, Takeda, Merck Sharp & Dohme, Immunoforge, Chugai Pharmaceutical Co., Ltd, Codagenix, Biotron Ltd, GlaxoSmithKline, Ennaid therapeutics, AbViro LLC, Medigen Vaccine Biologics Corp., Atea Pharmaceuticals, Visterra, Janssen Research & Development, Globavir Biosciences, Serum Institute of India, BioNet Asia, and others

  • Key Dengue Fever Pipeline Therapies: Research programs: anti-RNA virus therapeutics, viral budding inhibitors, ABX220, Infectious diseases therapeutics program, CDX DENV, AT-752, VIS513, JNJ-64281802, TV003, V 503, TAK-003, AV-1, PepGNP-Dengue, GBV 006, Dengushield, Pentavalent dengue-zika vaccine, and others

Dive deep into rich insights for emerging drugs and pipeline assessment, visit @ Dengue Fever Emerging Therapies

Table of Contents

1

Introduction

2

Executive Summary

3

Dengue Fever: Overview

4

Pipeline Therapeutics

5

Late Stage Products (Phase III)

5.1

V 503: Takeda

6

Late Stage Products (Phase III)

6.1

TV003: Merck & Co.

7

Mid Stage Products (Phase II)

7.1

JNJ-64281802: Janssen Research & Development

8

Early Stage Products (Phase I)

8.1

PepGNP-Dengue: Emergex Vaccines

9

Early Stage Products (Phase I)

9.1

VIS513: Visterra

10

Early Stage Products (Phase I)

10.1

AT-752: Atea Pharmaceuticals

11

Preclinical Stage Products

11.1

Infectious diseases therapeutics Programme: Plex Pharmaceuticals

12

Discovery Stage Products

13

Therapeutic Assessment

14

Inactive Products

15

Collaborations Licensing / Partnering / Funding

16

Dengue Fever - Unmet Needs

17

Dengue Fever - Market Drivers and Barriers

18

Appendix

19

About DelveInsight

For further information on the Dengue Fever current pipeline therapeutics, reach out @ Dengue Fever Ongoing Clinical Trials

Related Reports

Leishmaniasis Pipeline

DelveInsight’s, “Leishmaniasis - Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Leishmaniasis pipeline landscape. It covers the pipeline products by clinical, non-clinical stage therapies, and key Leishmaniasis companies such as Novartis, GlaxoSmithKline, MedC Biopharma Corporation, Drugs for Neglected Diseases Initiative Foundation, Infan Industria Quimica Farmaceutica Nacional, and others.

Malaria Pipeline

DelveInsight’s, “Malaria Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Malaria pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Malaria companies such as GlaxoSmithKline, Sanaria, Tarsus Pharmaceuticals, Novartis, Nobelpharma, Curevac, Novavax, and others.

Yellow Fever Pipeline

DelveInsight’s, “Yellow Fever Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Yellow Fever pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Yellow Fever companies such as BioCryst Pharmaceuticals, Tychan Pte Ltd, CureVac AG, Serum Institute of India Ltd, Sanofi, Emergex Vaccines, Imutex Ltd, and others.

Lassa Fever Pipeline

DelveInsight’s, “Lassa Fever Pipeline Insight, 2022,” report provides comprehensive insights about companies and pipeline drugs in the Lassa Fever pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Lassa Fever companies such as Curevac AG, Themis Bioscience, Inovio Pharmaceuticals, GeoVax, GloBavir biosciences Inc, Kineta Inc, and others.

Ebola Fever Pipeline

DelveInsight’s, “Ebola Fever Pipeline Insight, 2022,” report provides comprehensive insights about companies and pipeline drugs in the Ebola Fever pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Ebola Fever companies such as Jansen Pharmaceuticals, CanSino Biologics, Galactica Biotech Ltd, Gilead Sciences, GlaxoSmithKline, Greffex Inc, Integrated Biotherapeutics Inc, Inovio Pharmaceuticals, Merck & co, Johnson & Johnson, and others.

Familial Mediterranean Fever Pipeline

DelveInsight’s, “Familial Mediterranean Fever - Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Familial Mediterranean Fever pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Familial Mediterranean Fever companies such as Roche, and others.

Interested to know more about the breakthrough happenings? Take a look at the posts below

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com